Of the two human herpesvirus 6 (HHV-6) species, human herpesvirus 6B (HHV-6B) encephalitis is an important cause of morbidity and mortality after allogeneic hematopoietic stem cell transplant. Guidelines for the management of HHV-6 infections in patients with hematologic malignancies or post-transplant were prepared a decade ago but there have been no other guidelines since then despite significant advances in the understanding of HHV-6 encephalitis, its therapy, and other aspects of HHV-6 disease in this patient population. Revised guidelines prepared at the 2017 European Conference on Infections in Leukaemia covering diagnosis, preventative strategies and management of HHV-6 disease are now presented.

• MeSH
• Antiviral Agents pharmacology   therapeutic use   MeSH
• Hematologic Neoplasms complications   diagnosis   therapy   MeSH
• Immunocompromised Host MeSH
• Roseolovirus Infections diagnosis   etiology   therapy   MeSH
• Combined Modality Therapy MeSH
• Humans MeSH
• Herpesvirus 6, Human * MeSH
• Graft vs Host Disease etiology   MeSH
• Practice Guidelines as Topic * MeSH
• Hematopoietic Stem Cell Transplantation adverse effects   methods   MeSH
• Cell Transformation, Viral MeSH
• Treatment Outcome MeSH
• Check Tag
• Humans MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH
• Review MeSH
• Geographicals
• Europe MeSH
• Names of Substances
• Antiviral Agents MeSH